Page last updated: 2024-10-25

cimetidine and Urinary Bladder Neoplasms

cimetidine has been researched along with Urinary Bladder Neoplasms in 1 studies

Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.
cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.

Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chihara, Y1
Fujimoto, K1
Miyake, M1
Hiasa, Y1
Hirao, Y1

Other Studies

1 other study available for cimetidine and Urinary Bladder Neoplasms

ArticleYear
Anti-tumor effect of cimetidine via inhibiting angiogenesis factors in N-butyl-N-(4-hydroxybutyl) nitrosamine-induced mouse and rat bladder carcinogenesis.
    Oncology reports, 2009, Volume: 22, Issue:1

    Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Butylhydroxybutylnitrosamine; Cimetidine; Dow

2009